Cross-Sector entity
Of the tracked stories, 3 of 3 also mention Dentsply Sirona, the most common co-covered peer. The clearest coverage concentration is markets: 1 of 3 stories, with the rest divided among 2 other categories. Invenomic Capital Management appears in 3 tracked Cross-Sector stories from March 21, 2026.
3 verified stories tracked
Last mentioned: Mar 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Dentsply Sirona, the most common co-covered peer. The clearest coverage concentration is markets: 1 of 3 stories, with the rest divided among 2 other categories. Invenomic Capital Management appears in 3 tracked Cross-Sector stories from March 21, 2026. The tracked stories average 2 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Invenomic Capital Management. Shared-story counts are live from our verified record — not editorial picks.
Invenomic Capital Management has fully liquidated its $24.3 million stake in Haemonetics Corporation (HAE) following a period of significant market underperformance. The move signals a strategic shift for the fund as it reallocates capital toward more resilient healthcare and technology holdings.
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker. The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, a leader in blood and plasma management technology. The exit comes as the stock underperformed the broader market by 25% over the past year, signaling a shift in institutional sentiment toward the medical device sector.
Source: Jonathan Ponciano (us) · fool.com
